Wu-Ling-San (WLS) formula has been proved to prevent calcium oxalate nephrolithiasis both in vitro and in vivo. This is the first prospective, randomized and placebo-controlled clinical trial of WLS in calcium oxalate nephrolithiasis prevention. All patients who enrolled were asked to drink enough fluid to urinate at least 2 L daily during the study period. A 24-hour urine collection was performed to establish the baseline levels of multiple urinary parameters before taking the medicine. The patients were randomized and divided into two groups. The medication group took 2 gm WLS formula three times daily for 1 month. The control group took 2 gm placebo three times daily for 1 month. A 24-hour urine collection was performed to evaluate multiple urinary and serum parameters from all patients during the study period. A total of 39 patients were enrolled and 28 patients completed the study. Fourteen patients were allocated to WLS group and 14 patients to placebo group. After treatment, the mean urine output level increased to 2796.4  525.7 ml/day (percentage of change, 13.9 %) in the WLS formula group. With placebo therapy, the mean decreased slightly to 2521.4  762.7ml/day (percentage of change, -5.7 %). The percentage of change was significantly different between the two groups (independent t-test, P=0.02). No patient complained of side effects, such as fatigue, dizziness, musculoskeletal symptoms, or gastrointestinal disturbance. WLS formula is a promising adjunct to surgical and medical management of kidney stones. Active therapy with WLS formula has a positive effect on diuresis without leading to electrolyte imbalance.
Introduction
Urinary stone disease affects 9.6% of the total population in Taiwan, including 4.3% of females and 14.5% of males (Lee et al., 2002) . The recurrence rate ranges from 35% within 5 years and after first treatment to 74% within 10 years (Uribarri et al., 1989) . A number of medical treatments have been reported to prevent the recurrence of urinary stone, including encouraging patients to take more fluid, nutrient supplements and diet control (Lewandowski et al., 2004) .
In recent years, the most popular medication for preventing calcium oxalate nephrolithiasis has been potassium citrate (Barcelo et al., 1993; Ettinger et al., 1997; Hofbauer et al., 1994; Whalley et al., 1996) . Potassium citrate effectively reduces the recurrence rate of calcium oxalate nephrolithiasis (Hofbauer et al., 1994; Whalley et al., 1996) . However, potassium between the two groups, including age, male/female ratio, stone severity index, urolithiasis procedures and BMI ( Table 1 ).
The baseline urine output was 2485.7 ± 386.5ml/day (mean ± SD) in WLS group and 2732.1 ± 797.9 ml/day in placebo group. After treatment, the mean urine output level increased to 2796.4  525.7 ml/day (percentage of change, 13.9 %) in WLS formula group and decreased slightly to 2521.4  762.7ml/day (percentage of change, -5.7 %) in placebo group. The percentage of changes was significantly different between the two groups (independent t-test, P=0.02, Table 2 ).
The baseline serum BUN was 14.7  2.7mg/dl in WLS group and 15.04.6 mg/dl in placebo group. After treatment, the mean BUN level decreased to 13.8  3.9 mg/dl (percentage of change, -6.9 %) in WLS group and increased slightly to 16.9  5.3 mg/dl (percentage of change, 13.8 %) in placebo group. The percentage of change was significantly different between the two groups (independent t-test, P=0.006, Table 3 ). We believe that these results were related to the diuretic effect of WLS.
Commonly used drugs for urolithiasis prophylaxis, such as potassium citrate, alkalinize urine. We checked the urine pH before and after treatment. The baseline urine pH was 6.6  0.6 in WLS group and 6.3  0.8 in placebo group. After treatment, the urine pH was 6.5  0.7 (percentage of change, -0.02 %) in WLS formula group and 6.3  0.7 (percentage of change, 0.6%) in placebo group. The percentage of change between the WLS and placebo group was not significantly different (independent t-test, P=0.91, Table 2 ). These data suggested that WLS had no direct effect on urine pH.
For the study of possible drug toxicity, we checked the liver and renal function of patients before and after treatment. The percentage of change between the WLS and placebo group was not significantly different (independent t-test, P=0.25, Table 3 ). About renal function test, after treatment, the serum creatinine level was 1.1  0. between the WLS and placebo group was not significantly different (independent t-test, P=0.44, Table 3 ). Furthermore, the percentage of change of 24-hour Urine Ccr are slightly increased in WLS group than placebo group (26.2% versus 14.5%), but not significantly different (independent t-test, P=0.53, Table 2 ). These data suggested that WLS was safe and did not affect liver or renal function.
Urinary parameters, including 24-hour urine calcium and uric acid were checked. After treatment, the 24-hour urine calcium increased to 302.1  106.5mg/day (percentage of change, 44.6 %) in WLS formula group and 415.1  290.7mg/day (percentage of change, 62.7 %) in placebo group. The percentage of change in urinary calcium between the two groups was not significantly different (independent t-test, P=0.62). Similar results were noted on urine uric acid level. After treatment,
